Table 1.
Demographic and clinical features of patients with RA
| RA patients N = 352 | |
|---|---|
| Age, years | 61.8 (± 11.9) |
| Male, n (%) | 60 (17.0) |
| CCA-meanIMT, mm | 0.70 (± 0.16) |
| CCA-maxIMT, mm | 0.91 (± 0.33) |
| maxIMT ≥ 1.0 mm, n (%) | 83 (23.6) |
| Systolic BP, mmHg | 123.0 (± 17.1) |
| Current smoking, n (%) | 29 (8.2) |
| Family history of premature CVD, n (%) | 57 (16.2) |
| Statin use, n (%) | 34 (9.7) |
| Body composition indicators | |
| BMI, kg/m2 | 22.6 (± 3.6) |
| VFA, cm2 | 61.9 (± 32.5) |
| SFA, cm2 | 153.4 (± 70.0) |
| V/S ratio | 0.43 (± 0.19) |
| Systemic skeletal muscle ratio, % | 24.6 (± 3.2) |
| Waist circumference, cm | 84.1 (± 10.1) |
| Laboratory markers | |
| Total cholesterol, mg/dL | 200.0 (± 33.3) |
| HDL cholesterol, mg/dL | 70.7 (± 18.7) |
| LDL cholesterol, mg/dL | 115.0 (± 28.4) |
| Triglycerides, mg/dL | 88.7 (± 45.0) |
| eGFR, mL/min/1.73 m2 | 18.1 (± 18.1) |
| Comorbidities | |
| Hypertension, n (%) | 113 (32.1) |
| Diabetes, n (%) | 29 (8.2) |
| Dyslipidemia, n (%) | 130 (36.9) |
| RA disease characteristics | |
| RA duration, years | 7 (0.7–46) |
| RF, IU/mL | 39.0 (8-2833.6) |
| Anti-CCP, U/mL | 51.5 (0.6–3260) |
| CRP, mg/dL | 0.1 (0.1–9.6) |
| DAS28-ESR | 2.52 (0.33–7.20) |
| High, n (%) | 2 (0.6) |
| Moderate | 86 (24.4) |
| Low | 76 (21.6) |
| Remission | 188 (53.4) |
| Stage 1/2, n (%) | 103 (29.3)/95 (27.0) |
| 3/4 | 64 (18.1)/90 (25.6) |
| Class I/ II, n (%) | 188 (53.4)/146 (41.5) |
| III/ IV | 18 (5.1)/0 |
| Current RA therapeutics | |
| MTX use, n (%) | 255 (72.4) |
| MTX dosage, mg/week | 8 (2–16) |
| Other cs DMARD use, n (%) | 120 (34.0) |
| ts DMARD use, n (%) | 2 (0.01) |
| Biological agent use, n (%) | 183 (52.0) |
| Prednisolone use, n (%) | 74 (21.0) |
| Prednisolone dosage, mg/day | 4 (1–10) |
Values are shown as mean (± SD) or number (percentage). Values of RA disease characteristics and current RA therapeutics are shown as median (range)
RA rheumatoid arthritis, BMI Body Mass Index, VFA visceral fat area, SFA subcutaneous fat area, V/S ratio visceral fat area/subcutaneous area ratio, BP blood pressure, CVD cardiovascular disease, HDL high-density lipoprotein, LDL low-density lipoprotein, eGFR estimated glomerular filtration rat, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide, CRP C-reactive protein, DAS28-ESR 28-joint Disease Activity Score using erythrocyte sedimentation rate, MTX methotrexate, cs DMARD conventional synthetic disease modifying anti-rheumatic drugs, ts DMARD targeted synthetic DMARD